Skip to Content

Posts tagged with "Clinical Trials"

  • Cancer

    CAR-T Deaths Cannot Be Good

    Late yesterday afternoon, Matthew Herper broke the news that Juno Therapeutics had had their CAR-T leukemia trial put on hold after three patient deaths. That’s bad news no matter how you look at it, even for their competitors. It’s too early to say for sure if Juno will be slowed in its path to market. Read More
  • Cancer

    Can’t Shake Failure Yet

    From the new Endpoints site, here’s a roundup of the worst moments in the clinic for drug development in the first half of 2016. Several of them were covered at the time here as well, but there the whole list is worth a look, because it illustrates the many ways that big trouble can hit. Read More
  • "Me Too" Drugs

    PARP Inhibitors Come Through

    PARP (poly ADP-ribose polymerase) inhibitors have had a rough time of it in the clinic. Sanofi had one (iniparib) fail, but it later turned out, embarrassingly, that it wasn’t really a PARP inhibitor at all (update: more on this here). AstraZeneca had a legitimate one fail as well (olaparib). Merck got out of the area… Read More
  • Business and Markets

    The Immuno-oncology Traffic Jam

    Bruce Booth has a valuable look at the immuno-oncology field here. Everyone knows that it’s a hot area, but the numbers show that it’s even (better, worse) than you thought. There are at least 16 PD1/PDL1 programs in the clinic right now, and if  you count up all the preclinical programs that have been announced… Read More
  • Business and Markets

    Infinity’s Research, From Someone Who Was There

      Here’s a look from the inside at Infinity Pharmaceuticals, whose R&D operations hit the wall just recently. Keith Robison knows the company and its targets well, having worked there until about five years ago, and he provides a perspective that some others in the readership will have experienced as well: So it was a… Read More
  • Clinical Trials

    The Migraine Race

    Yesterday’s clinical trials news featured a therapy undone by a strong placebo response, so I wanted to mention another one that looks (at least from the outside) as if it came close. It’s erenumab, a joint project of Amgen and Novartis, and it’s an antibody directed towards the CGRP receptor for migraine. That’s been a mi… Read More
  • Business and Markets

    Pretty Intolerable, In the End

    Here’s a trivia question for you: What’s the biggest biotech IPO ever in the UK? They don’t have a huge history of floating new companies in the sector, but in 2014, Circassia raised $335 million (US$, 200 million pounds at the time). That was the first big initial offering in years on the London exchange and… Read More
  • Clinical Trials

    The NEJM and Clinical Trials: What’s Going On?

    Here’s an article from the New England Journal of Medicine on randomized clinical trials. You would expect one of the most well-known medical journals in the world to be in favor of clinical trials, but that doesn’t quite seem to be the case. The article is very much a on-the-one-hand on-the-other-hand affair: By the turn… Read More
  • Business and Markets

    Infinity’s Difficult History

    Infinity Pharmaceuticals today announced that it’s shutting down R&D operations. This comes after disappointing clinical results for a PI3K inhibitor it’s been developing (duvelisib), news which has sent the company’s stock down (at this moment) nearly 70%. And that comes after the 2012 failure of another clinical candidate, s… Read More
  • Biological News

    Ever Finer Splitting

    Charles Darwin once divided scientists into two types: “splitters” and “lumpers”. The splitters are the ones who keep finding finer distinctions between things that were once thought to be the same, and the lumpers, naturally, keep finding underlying similarities between things that were thought to be different. Recently, th… Read More